What happened
Daewoong Pharma filed provisional (unaudited) separate results for Q2 2026: revenue of US$277M (+10% year on year), operating profit of US$53.5M (+23.4% year on year) and net income of US$48.1M (+41.9% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$277M |
|---|---|
| Revenue vs a year earlier | +10% |
| Operating profit | US$53.5M |
| Net income | US$48.1M |
| Period | Q2 2026 (separate) |
| Filed | 2026-07-29, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260729800126 → open original filing |
Source: DART. Information only, not investment advice.